Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Journal of Clinical Pathology 65.2 (2012): S. 140-145.
- Keyword
-
-
Krebs
Onkologie
- Event
-
Veröffentlichung
- (where)
-
Erlangen
- (who)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (when)
-
2012
- Creator
-
Piscuoglio, Salvatore
Lehmann, Frank S.
Zlobec, Inti
Tornillo, Luigi
Dietmaier, Wolfgang
Hartmann, Arndt
Wünsch, Peter H.
Sessa, Fausto
Rümmele, Petra
Baumhoer, Daniel
Terracciano, Luigi Maria
- URN
-
urn:nbn:de:bvb:29-opus4-78142
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Piscuoglio, Salvatore
- Lehmann, Frank S.
- Zlobec, Inti
- Tornillo, Luigi
- Dietmaier, Wolfgang
- Hartmann, Arndt
- Wünsch, Peter H.
- Sessa, Fausto
- Rümmele, Petra
- Baumhoer, Daniel
- Terracciano, Luigi Maria
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Time of origin
- 2012
Other Objects (12)
Stem cell markers predict prognosis in breast cancer overall (EpCAM), and in subgroups of large (CD133), triple-negative (CD44), and hormone receptor positive carcinomas (CD166)
Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer
EpCAM is critical for tumor proliferation and oxaliplatin chemoresistance in EpCAM high/CD44 + colorectal cancer stem cells
Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis
A novel nitidine chloride nanoparticle overcomes the stemness of CD133+EPCAM+ Huh7 hepatocellular carcinoma cells for liver cancer therapy
Expression der Stammzellmarker CD133, CD44, Ki-A10 und CK19 in nichtneoplastischen und neoplastischen Pankreasgeweben
Oxytetracycline have the therapeutic efficiency in CD133+ HCC population through suppression CD133 expression by decreasing of protein stability of CD133
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
The role of CD133+ and EpCAM+ cancer stem cells in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and identification of new potential therapeutic targets
CD24, CD44 and EpCAM enrich for tumour-initiating cells in a newly established patient-derived xenograft of nasopharyngeal carcinoma
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+cells with cancer stem cell characteristics
Stem cell markers predict prognosis in breast cancer overall (EpCAM), and in subgroups of large (CD133), triple-negative (CD44), and hormone receptor positive carcinomas (CD166)
Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer
EpCAM is critical for tumor proliferation and oxaliplatin chemoresistance in EpCAM high/CD44 + colorectal cancer stem cells
Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis
A novel nitidine chloride nanoparticle overcomes the stemness of CD133+EPCAM+ Huh7 hepatocellular carcinoma cells for liver cancer therapy
Expression der Stammzellmarker CD133, CD44, Ki-A10 und CK19 in nichtneoplastischen und neoplastischen Pankreasgeweben
Oxytetracycline have the therapeutic efficiency in CD133+ HCC population through suppression CD133 expression by decreasing of protein stability of CD133
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
The role of CD133+ and EpCAM+ cancer stem cells in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and identification of new potential therapeutic targets
CD24, CD44 and EpCAM enrich for tumour-initiating cells in a newly established patient-derived xenograft of nasopharyngeal carcinoma
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+cells with cancer stem cell characteristics
Stem cell markers predict prognosis in breast cancer overall (EpCAM), and in subgroups of large (CD133), triple-negative (CD44), and hormone receptor positive carcinomas (CD166)
Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer
EpCAM is critical for tumor proliferation and oxaliplatin chemoresistance in EpCAM high/CD44 + colorectal cancer stem cells
Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis
A novel nitidine chloride nanoparticle overcomes the stemness of CD133+EPCAM+ Huh7 hepatocellular carcinoma cells for liver cancer therapy
Expression der Stammzellmarker CD133, CD44, Ki-A10 und CK19 in nichtneoplastischen und neoplastischen Pankreasgeweben
Oxytetracycline have the therapeutic efficiency in CD133+ HCC population through suppression CD133 expression by decreasing of protein stability of CD133
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
The role of CD133+ and EpCAM+ cancer stem cells in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and identification of new potential therapeutic targets
CD24, CD44 and EpCAM enrich for tumour-initiating cells in a newly established patient-derived xenograft of nasopharyngeal carcinoma